External Quality Assurance (EQA) Program

for

G6PD Screening and Quantitative Tests

¡@¡@Glucose-6-phosphate dehydrogenase (G6PD; EC1.1.1.49; MIM305900) deficiency is the most common enzymopathic in humans. A relatively high incidence (>2%) of this enzymopathy, which may cause of neonatal jaundice and acute hemolytic anemia, was found in Southeast Asia and some other tropical areas. If it is not prevented or treated properly, neonatal jaundice may lead to kernicterus and cause death or permanent neurological damage. The life-threatening hemolytic crises that occur later may cause permanent kidney damage and can be induced by certain drugs or by eating fava beans. In order to reduce these complications, neonatal screening for G6PD deficiency has been carried out in many countries in this region.

¡@¡@In order to assure the reliability and consistence of the G6PD neonatal screening and confirmatory tests among different laboratories, an external qaulity assurance (EQA) program for screening G6PD activity in neonatal dried blood spots and determination of G6PD activity in hemolysate has been carried out in Taiwan since 1988 and adopted by other newborn screening laboratories worldwide.

External Quality Assurance (EQA) for G6PD Newborn Screening Test

External Quality Assurance (EQA) for G6PD Quantitative Test in Taiwan

External Quality Assurance (EQA) for G6PD Quantitative Test in Philippines